Endocrine Abstracts

Introduction: According to the DSM-5, gender dysphoria (GD) is defined as a distress that results from an incongruence between one’s sex assigned at birth and one’s gender identity. This condition may require gender-affirming hormone therapy (GAHT), in order to reduce distress. GAHT, however, is not free from side effects and it could increase the risk of onset of new pathological conditions.Aim of the study: To evaluate cardiovascular comorbid...

Context: Glucocorticoids are known to decrease protein synthesis and impair membrane excitability of muscle fibres. However, their short-term effects on muscle structure and function of healthy subjects remain poorly understood.Objective: To investigate whether steroid administration could decrease the circulating levels of muscle proteins and modify myoelectric indexes of sarcolemmal excitability and fatigability.Design: Single-bl...

Background: Gender-affirming hormone treatment (GAHT) is the cornerstone in the therapeutic management of transgender and gender diverse (TGD) people, which are currently classified as transgender assigned-female-at birth (t-AFAB) and assigned-male-at birth (t-AMAB) subjects. Due to its hormonal nature, GAHT is commonly handled by the endocrinologist and available guidelines on this topic mimic the recommendations for cis-gender hypogonadal populations. However, the GAHT long ...